Detalhe da pesquisa
1.
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.
J Antimicrob Chemother
; 74(3): 710-717, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30541077
2.
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
J Neurovirol
; 25(1): 22-31, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30298202
3.
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
BMC Infect Dis
; 17(1): 256, 2017 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28399804
4.
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects.
BMC Infect Dis
; 16: 347, 2016 07 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27450277
5.
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine.
HIV Clin Trials
; 13(5): 233-44, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-23134624
6.
Estimated glomerular filtration rates through 144âweeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
HIV Clin Trials
; 16(4): 125-9, 2015 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26133089
7.
Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
HIV Clin Trials
; 11(2): 69-79, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20542844
8.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
PLoS One
; 14(11): e0225199, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31725787
9.
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Antivir Ther
; 13(5): 735-7, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-18771059
10.
Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.
AIDS Res Ther
; 5: 5, 2008 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-18373851
11.
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States.
AIDS Res Hum Retroviruses
; 34(8): 672-679, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29732898
12.
Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
HIV AIDS (Auckl)
; 9: 51-61, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28424561
13.
A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.
Clin Pharmacokinet
; 56(6): 661-669, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27699622
14.
Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
AIDS
; 19(1): 15-23, 2005 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-15627029
15.
Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens.
Open AIDS J
; 9: 38-44, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26157536
16.
Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Pediatr Infect Dis J
; 23(1): 15-22, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14743040
17.
Stavudine-associated peripheral neuropathy in zidovudine-naïve patients: effect of stavudine exposure and antiretroviral experience.
Adv Ther
; 19(1): 1-8, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12008857
18.
Pharmacokinetics, safety and antiviral activity of fosamprenavir/ritonavir-containing regimens in HIV-infected children aged 4 weeks to 2 years-48-week study data.
Pediatr Infect Dis J
; 33(1): 57-62, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811743
19.
Pharmacokinetics and 48-week safety and antiviral activity of fosamprenavir-containing regimens in HIV-infected 2- to 18-year-old children.
Pediatr Infect Dis J
; 33(1): 50-6, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811744
20.
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing.
PLoS One
; 9(2): e89611, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24586911